393 related articles for article (PubMed ID: 27921185)
1. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.
Ørnbjerg LM; Østergaard M; Jensen T; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Hetland ML; ; Slot O; Nielsen LK; Skjødt H; Majgaard O; Lorenzen T; Horn HC; Kowalski M; Johansen IL; Pedersen PM; Manilo N; Bliddal H
Clin Rheumatol; 2017 Apr; 36(4):781-789. PubMed ID: 27921185
[TBL] [Abstract][Full Text] [Related]
2. Structural joint damage and hand bone loss in patients with rheumatoid arthritis.
Ørnbjerg LM
Dan Med J; 2018 Mar; 65(3):. PubMed ID: 29510810
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Rezaei H; Saevarsdottir S; Geborek P; Petersson IF; van Vollenhoven RF; Forslind K
BMC Musculoskelet Disord; 2013 Mar; 14():79. PubMed ID: 23497111
[TBL] [Abstract][Full Text] [Related]
5. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
[TBL] [Abstract][Full Text] [Related]
6. Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up.
Hoff M; Haugeberg G; Odegård S; Syversen S; Landewé R; van der Heijde D; Kvien TK
Ann Rheum Dis; 2009 Mar; 68(3):324-9. PubMed ID: 18339664
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
[TBL] [Abstract][Full Text] [Related]
9. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
[TBL] [Abstract][Full Text] [Related]
10. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
[TBL] [Abstract][Full Text] [Related]
11. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study.
Hoff M; Kvien TK; Kälvesten J; Elden A; Haugeberg G
Ann Rheum Dis; 2009 Jul; 68(7):1171-6. PubMed ID: 18801760
[TBL] [Abstract][Full Text] [Related]
13. Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.
Ziegelasch M; Forslind K; Skogh T; Riklund K; Kastbom A; Berglin E
Arthritis Res Ther; 2017 Sep; 19(1):195. PubMed ID: 28865482
[TBL] [Abstract][Full Text] [Related]
14. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
15. Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Wevers-de Boer KV; Heimans L; Visser K; Kälvesten J; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Steup-Beekman M; de Buck MP; de Sonnaville PB; Huizinga TW; Allaart CF
Ann Rheum Dis; 2015 Feb; 74(2):341-6. PubMed ID: 24285491
[TBL] [Abstract][Full Text] [Related]
16. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS
Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743
[TBL] [Abstract][Full Text] [Related]
17. Hand bone loss measured by digital X-ray radiogrammetry is a predictor of joint damage in early rheumatoid arthritis.
Forslind K; Boonen A; Albertsson K; Hafström I; Svensson B;
Scand J Rheumatol; 2009; 38(6):431-8. PubMed ID: 19922017
[TBL] [Abstract][Full Text] [Related]
18. Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry.
Szentpetery A; Heffernan E; Haroon M; Kilbane M; Gallagher P; McKenna MJ; FitzGerald O
Rheumatology (Oxford); 2016 May; 55(5):891-6. PubMed ID: 26850991
[TBL] [Abstract][Full Text] [Related]
19. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
[TBL] [Abstract][Full Text] [Related]
20. Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study.
Ørnbjerg LM; Østergaard M; Jensen T; Hyldstrup L; Bach-Mortensen P; Bøyesen P; Thormann A; Tarp U; Bøhme WP; Lindegaard H; Poulsen UE; Schlemmer A; Graudal N; Rødgaard A; Espesen J; Kollerup GB; Glintborg B; Madsen OR; Jensen DV; Hetland ML
Arthritis Res Ther; 2016 Feb; 18():53. PubMed ID: 26912229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
